- Home
- HERZ vs ATNM Comparison
HERZ vs ATNM Comparison
Compare HERZ & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | ATNM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 31.4M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HERZ | ATNM |
|---|---|---|
| Price | $13.90 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 14.3K | ★ 228.2K |
| Earning Date | N/A | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | $38,788.89 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.97 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.62 | $0.74 |
| 52 Week High | $19.30 | $1.72 |
Technical Indicators
Market Signals| Indicator | HERZ | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 23.35 | 62.23 |
| Support Level | $1.62 | $0.97 |
| Resistance Level | $16.66 | $1.53 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 6.41 | 67.61 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.